一种评估代谢酶3βHSD1活性的方法及系统
By establishing a transcriptome fingerprint score assessment method based on decision tree and random forest models, the problem of assessing the activity of the metabolic enzyme 3βHSD1 was solved, enabling accurate prediction of the risk of malignant transformation of prostate cancer and supporting early diagnosis and treatment.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- HANGZHOU INST FOR ADVANCED STUDY UCAS
- Filing Date
- 2023-12-01
- Publication Date
- 2026-07-17
AI Technical Summary
Current technologies cannot effectively assess the activity of the metabolic enzyme 3βHSD1, resulting in low accuracy in predicting prostate cancer malignancy in the Chinese population, which fails to meet clinical needs.
By collecting gene expression data from the prostate tissue of subjects, decision tree models and random forest models were established to calculate transcriptomic fingerprint scores and assess the activity of the metabolic enzyme 3βHSD1, thus assisting in the assessment of the risk of prostate cancer malignancy.
It provides a method for assessing the activity of the metabolic enzyme 3βHSD1 applicable to the Chinese population, which improves the accuracy of predicting the malignant trend of prostate cancer and supports early diagnosis and treatment.
Smart Images
Figure CN117809745B_ABST